(Q37811594)

23 August 2017

1 reference

title

Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile (English)

1 reference

23 August 2017

1 reference

1 reference

1

Brogden RN

1 reference

23 August 2017

Buckley MM

2

1 reference

PubMed ID

2109679

23 August 2017

Ward A

series ordinal

3

1 reference

23 August 2017

1 March 1990

1 reference

23 August 2017

1 reference

23 August 2017

39

1 reference

23 August 2017

3

1 reference

23 August 2017

399-437

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199039030-00007

23 August 2017

0 references

cites work

Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men

1 reference

12 December 2020

Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly-NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men

1 reference

12 December 2020

Response of luteinizing hormone from columns of dispersed rat pituitary cells to a highly potent analogue of luteinizing hormone releasing hormone

1 reference

12 December 2020

The use of a GnRH analogue for ovulation induction for tubal gamete transfer

1 reference

12 December 2020

Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression

1 reference

12 December 2020

Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase

1 reference

12 December 2020

Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas

1 reference

12 December 2020

Addition of Buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT

1 reference

12 December 2020

The effect of D-ser (TBU)6-LH-RH-EA10 upon gonadotropin release in normally cyclic women

1 reference

12 December 2020

Luteolysis induced by a luteinizing hormone-releasing hormone agonist is prevented by human chorionic gonadotropin

1 reference

12 December 2020

Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.

1 reference

12 December 2020

Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration

1 reference

12 December 2020

Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding

1 reference

12 December 2020

Endocrine changes following pituitary desensitization with LHRH agonist and administration of purified FSH to induce follicular maturation

1 reference

12 December 2020

Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations

1 reference

12 December 2020

Use of LHRH agonists and antagonists in male contraception: A review

1 reference

12 December 2020

Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate

1 reference

12 December 2020

Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach

1 reference

12 December 2020

CAF and nasal buserelin in the treatment of premenopausal women with metastatic breast cancer

1 reference

12 December 2020

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice

1 reference

12 December 2020

Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy

1 reference

12 December 2020

Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women

1 reference

12 December 2020

Buserelin as primary therapy in advanced prostatic carcinoma

1 reference

12 December 2020

Combined effects of Buserelin, estradiol and Tamoxifen on the growth of MCF-7 human breast cancer cells in vitro

1 reference

12 December 2020

Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin)

1 reference

12 December 2020

Interference in follicular maturation following acute intranasal LH-RH agonist administration during mid and late follicular phase

1 reference

12 December 2020

Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome

1 reference

12 December 2020

Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol

1 reference

12 December 2020

Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach

1 reference

12 December 2020

A new systematic treatment for infertile women with abnormal hormone profiles

1 reference

12 December 2020

LRH agonist buserelin as a post-partum contraceptive: lack of biological activity of buserelin in breast milk

1 reference

12 December 2020

Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma

1 reference

12 December 2020

Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide)

1 reference

12 December 2020

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

1 reference

12 December 2020

Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.

1 reference

12 December 2020

A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis

1 reference

12 December 2020

Comparison of long-acting analogues of luteinizing hormone releasing hormone in man

1 reference

12 December 2020

Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue

1 reference

12 December 2020

Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase

1 reference

12 December 2020

Morphological studies of human endometrium during continuous LH-RH agonist treatment

1 reference

12 December 2020

Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin.

1 reference

12 December 2020

Evaluation of buserelin (LHRHa) in the management of precocious puberty

1 reference

12 December 2020

Premenstrual exacerbations in hepatic porphyria: prevention by intermittent administration of an LH-RH agonist in combination with a gestagen

1 reference

12 December 2020

Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: hormonal evaluations and clinical perspectives.

1 reference

12 December 2020

Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin

1 reference

12 December 2020

Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis

1 reference

12 December 2020

Inhibition of ovulation in women by chronic treatment with a stimulatory lrh analogue — A new approach to birth control?

1 reference

12 December 2020

Homologous Regulation of Gonadotropin-Releasing Hormone Receptors in Cultured Pituitary Cells

1 reference

12 December 2020

Increased bone pain after suspension of buserelin treatment in disseminated prostatic cancer

1 reference

12 December 2020

Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist

1 reference

12 December 2020

Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist

1 reference

12 December 2020

Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist

1 reference

12 December 2020

Reversible inhibition of central precocious puberty with a long acting GnRH analogue

1 reference

12 December 2020

Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone

1 reference

12 December 2020

Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives

1 reference

12 December 2020

Successful treatment of infertility due to polycystic ovary disease using a combination of luteinising hormone releasing hormone agonist and low dosage menotrophin

1 reference

12 December 2020

1 reference

12 December 2020

The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT

1 reference

12 December 2020

Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study

1 reference

12 December 2020

LHRH analogues and bone loss

1 reference

12 December 2020

Treatment of prostatic cancer with LH-RH analogues

1 reference

12 December 2020

Prostate cancer: clinical trials of gonadotrophin-releasing hormone analogs as an alternative to orchiectomy

1 reference

12 December 2020

Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin

1 reference

12 December 2020

Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme

1 reference

12 December 2020

Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist

1 reference

12 December 2020

Luteinising hormone releasing hormone agonist in women with endometriosis.

1 reference

12 December 2020

Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease.

1 reference

12 December 2020

[Clinical experiences in the treatment of endometriosis with the LH-RH analog buserelin with special reference to the post-therapy course]

1 reference

12 December 2020

Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?

1 reference

12 December 2020

Sustained gonadal suppression in fertile women with the LHRH agonist buserelin

1 reference

12 December 2020

Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach

1 reference

12 December 2020

Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis

1 reference

12 December 2020

Combined gonadotropin-releasing hormone analog and exogenous gonadotropins for ovulation induction in infertile women: efficacy related to ovarian function assessment

1 reference

12 December 2020

Dose-response study with a new LH-RH analogue, D-Ser (TBU)6 LH-RH 1-9 (EA)10 during the follicular phase of the menstrual cycle

1 reference

12 December 2020

The regulation of LHRH action at the pituitary and gonadal receptor level: A review

1 reference

12 December 2020

Treatment of prostate cancer with gonadotropin-releasing hormone agonists

1 reference

12 December 2020

Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis

1 reference

12 December 2020

Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.

1 reference

12 December 2020

Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization

1 reference

12 December 2020

Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate

1 reference

12 December 2020

Treatment of central precocious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment

1 reference

12 December 2020

Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue

1 reference

12 December 2020

Effects of LH suppression in polycystic ovary syndrome

1 reference

12 December 2020

Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue

1 reference

12 December 2020

[Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application]

1 reference

12 December 2020

Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography

1 reference

12 December 2020

Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis

1 reference

12 December 2020

LH-RH agonist treatment of endometriosis

1 reference

12 December 2020

[Gonadotropin stimulation and in vitro fertilization following selective hypophyseal suppression by LH/RH analogs]

1 reference

12 December 2020

Gonadotrophin responses to GnRH in precocious puberty treated with GnRH analogue

1 reference

12 December 2020

Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns

1 reference

12 December 2020

Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment

1 reference

12 December 2020

Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase

1 reference

12 December 2020

Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer

1 reference

12 December 2020

Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma

1 reference

12 December 2020

Short-term utilization of a gonadotropin-releasing hormone agonist (buserelin) for induction of ovulation in an in vitro fertilization program

1 reference

12 December 2020

Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life

1 reference

12 December 2020

Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin).

1 reference

12 December 2020

Gonadotrophin releasing hormone receptors and the response of pituitary gonadotrophs in culture

1 reference

12 December 2020

Absence of a direct inhibitory effect of the gonadotropin-releasing hormone (GnRH) agonist D-Ser (TBU)6, des-Gly-NH2(10) GnRH ethylamide (Buserelin) on testicular steroidogenesis in men

1 reference

12 December 2020

Studies with fragments of a highly active analogue of luteinizing hormone releasing hormone

1 reference

12 December 2020

Antibody production against an agonist analogue of luteinizing hormone-releasing hormone: evaluation of immunochemical and physiological consequences

1 reference

12 December 2020

Investigations of the carcinogenicity of the LH-RH analog buserelin (HOE 766) in rats using the subcutaneous route of administration

1 reference

12 December 2020

Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients

1 reference

12 December 2020

Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin

1 reference

12 December 2020

Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women

1 reference

12 December 2020

Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells

1 reference

12 December 2020

The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty

1 reference

12 December 2020

A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients

1 reference

12 December 2020

[Treatment of central precocious puberty with an LHRH analog. Effect on growth and bone maturation after 2 years of treatment]

1 reference

12 December 2020

LHRH-agonist treatment in metastatic prostate carcinoma

1 reference

12 December 2020

Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome

1 reference

12 December 2020

Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol

1 reference

12 December 2020

Use of LHRH agonists in the treatment of anovulation in women with polycystic ovary syndrome

1 reference

12 December 2020

Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty

1 reference

12 December 2020

Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer

1 reference

12 December 2020

Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects

1 reference

12 December 2020

Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.

1 reference

12 December 2020

Pregnancy following induction of ovulation with pure FSH after suppression of endogenous gonadotropins with subcutaneous buserelin

1 reference

12 December 2020

Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

1 reference

12 December 2020

Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease

1 reference

12 December 2020

Efficacy of buserelin in advanced prostate cancer and comparison with historical controls

1 reference

12 December 2020

New aspects of the physiological significance of LRH receptors of pituitary plasma membranes

1 reference

12 December 2020

Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins

1 reference

12 December 2020

The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.

1 reference

12 December 2020

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Using Different Modes of Application

1 reference

12 December 2020

A long term follow-up of patients with advanced prostatic cancer treated with buserelin

1 reference

12 December 2020

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens

1 reference

12 December 2020

Direct inhibition of testicular function by gonadotropin-releasing hormone: mediation by specific gonadotropin-releasing hormone receptors in interstitial cells

1 reference

12 December 2020

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer

1 reference

12 December 2020

Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters

1 reference

12 December 2020

Increased incidence of ovarian hyperstimulation syndrome following combined GnRH agonist/hMG therapy

1 reference

12 December 2020

Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer

1 reference

12 December 2020

The proof of drug effects on endocrine glands or endocrine target organs by means of toxicological investigations

1 reference

12 December 2020

The pituitary-gonadal response to the gonadotrophin releasing hormone analogue D-Ser (TBU)6-Des Gly10-LHRH-ethylamide in normal men

1 reference

12 December 2020

Acute pituitary-ovarian response during chronic luteinizing hormone-releasing hormone agonist administration in polycystic ovarian syndrome

1 reference

12 December 2020

Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?

1 reference

12 December 2020

Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience)

1 reference

12 December 2020

Failure of high-dose sustained release luteinizing hormone releasing hormone agonist (buserelin) plus oral testosterone to suppress male fertility.

1 reference

12 December 2020

Response of the benign hypertrophied prostate to treatment with an LHRH analogue

1 reference

12 December 2020

Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients

1 reference

12 December 2020

A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization

1 reference

12 December 2020

LHRH-analogues therapy for metastatic prostate cancer

1 reference

12 December 2020

Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion.

1 reference

12 December 2020

Buserelin suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment

1 reference

12 December 2020

Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach

1 reference

12 December 2020

Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens

1 reference

12 December 2020

Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study

1 reference

12 December 2020

Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men

1 reference

12 December 2020

Luteolytic Effect of Intranasal Administration of [D-Ser(TBU)6,des-Gly-NH210]-Luteinizing Hormone-Releasing Hormone Ethylamide in Normal Women

1 reference

12 December 2020

Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses

1 reference

12 December 2020

Total androgen blockade for metastatic cancer of the prostate

1 reference

12 December 2020

Newborn and immature rat testes contain gonadotropin-releasing hormone (GnRH) receptors, and their testosterone production is stimulated by a GnRH agonist in vitro

1 reference

12 December 2020

A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate

1 reference

12 December 2020

10.2165/00003495-199039030-00007

Identifiers

DOI

1 reference

PubMed ID

2109679

Dimensions Publication ID

23 August 2017

0 references

1 reference

PubMed ID

2109679